Compare Equinix Inc (EQIX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Equinix Inc trades at $995.9 (market cap $100.59B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Equinix Inc is far larger — about 103.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Equinix Inc pays a 2.02% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EQIX | MRVI | |
|---|---|---|
Market Cap | $100.59B | $972.90M |
Volume | 409,185 | 4,325,710 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $9.00 |
52-Week Low | $726.09 | $2.83 |
Typical Hold Time | 110 Days | 0 Days |
Enterprise Value | $121.72B | $1.08B |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $995.9, down 3.55% today, amid mixed technical signals but strong analyst support. The stock shows bullish moving averages and neutral oscillators, with key support at $1,008. Fundamentally, revenue grew to $9.22B in 2025 with a net income margin of 15.63%, though valuation ratios remain elevated with a P/E of 65.6. Recent news highlights AI-driven data center demand and a $5B-$7B annual expansion plan, positioning EQIX for growth despite recent earnings misses.
Outlook: EQIX benefits from robust AI and interconnection demand, with a consensus price target of $1,250 implying ~25% upside. Risks include high capital expenditures, debt levels rising to 47.13% of assets, and execution challenges in a competitive sector. The strong buy rating (75% of analysts) and dividend yield support a positive medium-term view, but investors should monitor capex efficiency and quarterly earnings consistency.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
